Return to Listing

8 result(s) for Lung Cancers

PI Name Protocol # Title
Jeremy Cetnar IRB00011046 [NCI CIRB]S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Khaled Tolba IRB00011462 A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Jeremy Cetnar IRB00011845 A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-LI Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naïve Patients Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Khaled Tolba IRB00012012 A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of MPDL3280A (ANTI−PD-L1 ANTIBODY) Compared With Best Supportive Care Following adjuvant Cisplatin-Based Chemotherapy In PD-L1−Selected Patients With Completely Resected STAGE IB−IIIA
Karen Lyons STUDY00015498 Together: A Pilot Study of Young and Middle-Aged Couples with Cancer in Rural and Urban Areas
Jeremy Cetnar STUDY00015662 CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
Jeremy Cetnar STUDY00016256 TO-TAS-114-201: A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination with S-1 in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
Khaled Tolba STUDY00016349 [Quorum] CINC280A2201: A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080